Contribution: Industrial Research Assistance Program – Contributions to Firms
Immune Biosolutions inc.
$490,750.00
Development of recombinant multispecific antibodies in immuno-oncology simultaneously targeting tumor-associated antigens, tumor invasion and immune system modulation
FY 2022-23 · 2022-08-05
Summary
The main objective of the project is to develop at least one bispecific or multispecific therapeutic antibody in pulmonary immuno-oncology. To this end, the company will improve its platform to accelerate the therapeutic antibody discovery process through the implementation of new technologies, automation and high throughput processing of the experimental data collected. This platform will be able to efficiently generate multispecific antibodies with demonstrated therapeutic efficacy.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Sherbrooke|Sherbrooke, Quebec, Canada
Recipient Type
For-profit organization
Business Number
805852886
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2022-08-05 | 2022-23 | $490,750.00 |
| 1 | 2022-08-05 | 2022-23 | $490,750.00 |
| 2 | 2022-08-05 | 2022-23 | $490,750.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 47 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 47 jours.
Agreement End Date
2024-01-31
Agreement Number
993841
Agreement Start Date
2022-08-05
Agreement Title
Development of recombinant multispecific antibodies in immuno-oncology simultaneously targeting tumor-associated antigens, tumor invasion and immune system modulation
Agreement Title (French)
Développement d'anticorps recombinants multi-spécifiques en immuno-oncologie ciblant simultanément des antigènes associés à la tumeur, l'invasion tumorale et la modulation du système immunitaire
Agreement Type
Contribution
Agreement Value
$490,750.00
Amendment Date
2023-10-17
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The main objective of the project is to develop at least one bispecific or multispecific therapeutic antibody in pulmonary immuno-oncology. To this end, the company will improve its platform to accelerate the therapeutic antibody discovery process through the implementation of new technologies, automation and high throughput processing of the experimental data collected. This platform will be able to efficiently generate multispecific antibodies with demonstrated therapeutic efficacy.
Description (French)
Le projet a pour objectif principal de développer au minimum un anticorps thérapeutique bispécifique ou multispécifique en immuno-oncologie pulmonaire.
À cette fin, l’entreprise va améliorer sa plateforme pour accélérer le processus de découverte d’anticorps thérapeutique via l’implémentation de nouvelles technologies, l’automatisation et le traitement à haut-débit des données expérimentales recueillies. Cette plateforme sera en mesure de générer efficacement des anticorps multispécifiques ayant une efficacité thérapeutique démontrée.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Sherbrooke
Federal Riding (French)
Sherbrooke
Federal Riding Number
24073
NAICS Code
54171
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
805852886
Recipient City
Sherbrooke|Sherbrooke
Recipient Country
CA
Recipient Legal Name
Immune Biosolutions inc.
Recipient Operating Name
Immune Biosolutions
Recipient Postal Code
J1E 0M8
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2022-2023-Q2-993841
